X4 Pharmaceuticals (XFOR) Change in Cash (2017 - 2025)
X4 Pharmaceuticals' (XFOR) quarterly Change in Cash came in at $147.4 million in Q4 2025, up 453.31% YoY from $26.6 million in Q4 2024, and up 384.72% on a QoQ basis from $30.4 million in Q3 2025.
X4 Pharmaceuticals (XFOR) Change in Cash (2017 - 2025) Analysis & Trends
X4 Pharmaceuticals (XFOR) has 9 years of Change in Cash data on file, last reported at $147.4 million in Q4 2025.
- Quarterly Change in Cash rose 453.31% year-over-year to $147.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $161.4 million (up 468.67% YoY) and the FY2025 annual result came in at $161.4 million, up 468.67% from the prior year.
- Change in Cash rose to $147.4 million in Q4 2025, from $30.4 million in the prior quarter.
- In the past five years, Change in Cash ranged from a high of $147.4 million in Q4 2025 to a low of -$49.8 million in Q3 2024.
- A 5-year average of $6.9 million and a median of -$10.1 million in 2022 frame the typical range for Change in Cash.
- Annual changes were most pronounced in 2022 — Change in Cash jumped 677.28% — and 2024, when it sank 926.3%.
- Tracing XFOR's Change in Cash over 5 years: stood at $5.4 million in 2021, then jumped by 677.28% to $41.9 million in 2022, then sank by 177.26% to -$32.4 million in 2023, then dropped by 28.96% to -$41.7 million in 2024, then jumped by 453.31% to $147.4 million in 2025.
- The last three Change in Cash figures came in at $147.4 million (Q4 2025), $30.4 million (Q3 2025), and -$1.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 427.25 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.97 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -2.94 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.42 Mn |
| 10 | X4 Pharmaceuticals | 533.17 Mn | 338.08 Mn | 7.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 147.42 Mn |
| Sep 30, 2025 | 30.41 Mn |
| Jun 30, 2025 | -1.02 Mn |
| Mar 31, 2025 | -15.43 Mn |
| Dec 31, 2024 | -41.73 Mn |
| Sep 30, 2024 | -49.80 Mn |
| Jun 30, 2024 | 86.73 Mn |
| Mar 31, 2024 | -38.98 Mn |
| Dec 31, 2023 | -32.36 Mn |
| Sep 30, 2023 | -4.85 Mn |
| Jun 30, 2023 | 43.02 Mn |
| Mar 31, 2023 | -28.60 Mn |
| Dec 31, 2022 | 41.88 Mn |
| Sep 30, 2022 | 32.47 Mn |
| Jun 30, 2022 | -19.06 Mn |
| Mar 31, 2022 | -15.36 Mn |
| Dec 31, 2021 | 5.39 Mn |
| Sep 30, 2021 | -18.77 Mn |
| Jun 30, 2021 | -20.17 Mn |
| Mar 31, 2021 | 35.96 Mn |